Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT

Table 3 Treatment predicting infections, for all persons and among those deficient in 25(OH)D at baseline at varying thresholds

			Number of participants with baseline 25(OH)D at level specified (%)	All infections		Infections seen in clinic
				Unadjusted	Adjusted^a	Unadjusted	Adjusted^a
All persons		Placebo	16 (47.1)	1.00 [reference]	1.00 [reference]	1.00 [reference]	1.00 [reference]
		Placebo	16 (47.1)	0.83 (0.53, 1.31)	0.80 (0.50, 1.30)	0.86 (0.50, 1.50)	0.87 (0.52, 1.46)
		Treatment	18 (52.9)	P = 0.42	P = 0.37	P = 0.60	P = 0.60
25(OH)D threshold (nmol/L)	≤40	Placebo	2 (50.0)	1.00 [reference]	1.00 [reference]	1.00 [reference]	1.00 [reference]
		Treatment	2 (50.0)	0.56 (0.32, 0.96)^b	0.41 (0.22, 0.78)^b	0.27 (0.07, 1.00)^b	0.26 (0.06, 1.17)
		Treatment	2 (50.0)	P = 0.036^b	P = 0.007^b	P = 0.050^b	P = 0.079
	≤50	Placebo	4 (50.0)	1.00 [reference]	1.00 [reference]	1.00 [reference]	1.00 [reference]
		Treatment	4 (50.0)	0.61 (0.38, 0.98)^b	0.68 (0.34, 1.34)	0.48 (0.18, 1.30)	0.57 (0.18, 1.78)
		Treatment	4 (50.0)	P = 0.043^b	P = 0.27	P = 0.15	P = 0.34
	≤60	Placebo	4 (40.0)	1.00 [reference]	1.00 [reference]	1.00 [reference]	1.00 [reference]
		Treatment	6 (60.0)	0.86 (0.54, 1.35)	1.02 (0.60, 1.72)	0.66 (0.34, 1.30)	0.74 (0.36, 1.56)
		Treatment	6 (60.0)	P = 0.50	P = 0.95	P = 0.23	P = 0.43
	≤70	Placebo	5 (29.4)	1.00 [reference]	1.00 [reference]	1.00 [reference]	1.00 [reference]
		Treatment	12 (70.6)	0.80 (0.51, 1.25)	0.82 (0.48, 1.41)	0.95 (0.46, 1.97)	0.85 (0.42, 1.70)
		Treatment	12 (70.6)	P = 0.33	P = 0.48	P = 0.89	P = 0.64

Results are presented as HR (95% CI).
25(OH)D 25-hydroxyvitamin D, nmol/L nanomoles per litre.
^aAnalyses adjusted for age, sex, ever smoking and days per week engaging in vigorous physical activity.
^bStatistically significant.

ISSN: 2055-0928